Treat the VTE and worry less about the hemorrhage: A sigh of relief or is the jury still out for therapeutic anticoagulation in high-grade glioma?
作者信息
Taylor Jennie W
机构信息
Departments of Neurology and Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
出版信息
Neuro Oncol. 2022 Mar 12;24(3):465-466. doi: 10.1093/neuonc/noab277.
Abstract
摘要
相似文献
1
Treat the VTE and worry less about the hemorrhage: A sigh of relief or is the jury still out for therapeutic anticoagulation in high-grade glioma?治疗静脉血栓栓塞症，减少对出血的担忧：松一口气还是在高级别胶质瘤的治疗性抗凝方面仍尚无定论？
Neuro Oncol. 2022 Mar 12;24(3):465-466. doi: 10.1093/neuonc/noab277.
2
Venous thrombosis in patients with high-grade glioma.高级别胶质瘤患者的静脉血栓形成
Curr Opin Oncol. 2015 Nov;27(6):516-21. doi: 10.1097/CCO.0000000000000226.
3
Anticoagulation of malignant glioma patients in the era of novel antiangiogenic agents.新型抗血管生成药物时代恶性脑胶质瘤患者的抗凝治疗。
Curr Opin Neurol. 2010 Dec;23(6):592-6. doi: 10.1097/WCO.0b013e32833feb73.
4
Management of venous thromboembolism in patients with glioma.脑胶质瘤患者静脉血栓栓塞症的管理。
Thromb Res. 2017 Aug;156:105-108. doi: 10.1016/j.thromres.2017.06.010. Epub 2017 Jun 8.
5
Management of venous thromboembolism in high-grade glioma: Does low molecular weight heparin increase intracranial bleeding risk?高级别胶质瘤患者静脉血栓栓塞症的管理：低分子肝素是否会增加颅内出血风险？
Neuro Oncol. 2022 Mar 12;24(3):455-464. doi: 10.1093/neuonc/noab198.
6
Safety of apixaban for venous thromboembolic primary prophylaxis in patients with newly diagnosed malignant glioma.阿哌沙班用于新诊断恶性胶质瘤患者静脉血栓栓塞一级预防的安全性
J Thromb Thrombolysis. 2022 Feb;53(2):479-484. doi: 10.1007/s11239-021-02537-w. Epub 2021 Aug 4.
7
Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin.预测接受治疗性依诺肝素的脑肿瘤患者颅内出血发生率更高。
Blood. 2017 Jun 22;129(25):3379-3385. doi: 10.1182/blood-2017-02-767285. Epub 2017 May 3.
8
Predictors of recurrent venous thromboembolism and bleeding on anticoagulation.抗凝治疗中复发性静脉血栓栓塞和出血的预测因素。
Thromb Res. 2016 Apr;140 Suppl 1:S93-8. doi: 10.1016/S0049-3848(16)30106-2.
9
Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients.贝伐珠单抗治疗与抗凝治疗在胶质瘤患者中的安全性。
J Neurooncol. 2012 Jan;106(1):121-5. doi: 10.1007/s11060-011-0642-1. Epub 2011 Jun 26.
10
Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.直接口服抗凝剂用于静脉血栓栓塞症的延长治疗：来自 EINSTEIN CHOICE 研究的见解。
Blood Transfus. 2020 Jan;18(1):49-57. doi: 10.2450/2019.0265-18. Epub 2019 Apr 30.
本文引用的文献
1
Management of venous thromboembolism in high-grade glioma: Does low molecular weight heparin increase intracranial bleeding risk?高级别胶质瘤患者静脉血栓栓塞症的管理：低分子肝素是否会增加颅内出血风险？
Neuro Oncol. 2022 Mar 12;24(3):455-464. doi: 10.1093/neuonc/noab198.
2
SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors.SNO 和 EANO 实践指南更新：新诊断脑肿瘤患者的抗惊厥预防。
Neuro Oncol. 2021 Nov 2;23(11):1835-1844. doi: 10.1093/neuonc/noab152.
3
Intracerebral haemorrhage in patients with brain metastases receiving therapeutic anticoagulation.接受治疗性抗凝的脑转移患者的脑出血
J Neurol Neurosurg Psychiatry. 2021 Mar 9. doi: 10.1136/jnnp-2020-324488.
4
Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype.二级至四级胶质瘤中静脉血栓栓塞风险与分子亚型的关系。
Neurology. 2021 Feb 16;96(7):e1063-e1069. doi: 10.1212/WNL.0000000000011414. Epub 2020 Dec 22.
5
Risk of intracranial bleeding in patients with primary brain cancer receiving therapeutic anticoagulation for venous thromboembolism: A meta-analysis.原发性脑癌患者接受治疗性抗凝治疗静脉血栓栓塞症的颅内出血风险：一项荟萃分析。
Brain Behav. 2020 Jun;10(6):e01638. doi: 10.1002/brb3.1638. Epub 2020 Apr 21.
6
Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin.预测接受治疗性依诺肝素的脑肿瘤患者颅内出血发生率更高。
Blood. 2017 Jun 22;129(25):3379-3385. doi: 10.1182/blood-2017-02-767285. Epub 2017 May 3.
7
Thromboembolic disease in patients with high-grade glioma.高级别胶质瘤患者的血栓栓塞性疾病。
Neuro Oncol. 2012 Sep;14 Suppl 4(Suppl 4):iv73-80. doi: 10.1093/neuonc/nos197.
Zotero 插件